Explore mots-c/humanin blend calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.
Anonymized mots-c/humanin blend calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.
The MOTS-C/Humanin Blend combines two mitochondrial-derived peptides — MOTS-c and humanin — in one research product, most often sourced for metabolic and cellular-aging research. It ships as a lyophilized powder you reconstitute with bacteriostatic water. See the standalone MOTS-c and Humanin entries for full per-component pharmacology.[1][2]
The combination has no blend-specific mechanism in the published literature; each component acts through its own established pathway. MOTS-c activates AMPK and modulates the folate-methionine cycle; humanin binds intracellular Bax to inhibit apoptosis and signals extracellularly through CNTFR/WSX-1/gp130 to activate STAT3.[1][2][3] The blend is a convenience formulation, not a fixed-ratio combination with documented synergy.
No peer-reviewed clinical or pre-clinical study has evaluated this specific blend or its dose ratio. The single-component literature for MOTS-c (metabolic, insulin-sensitivity, healthspan) and humanin (neuroprotection, anti-apoptotic, insulin-sensitivity) is reviewed in their respective entries.[1][2][3][4] No registered ClinicalTrials.gov trial exists for any MDP blend.[5]
Not FDA-approved. No clinical or pre-clinical study of the specific blend. Research-grade material only — each component is investigational with rodent and observational data only.
MOTS-C/Humanin Blend has a reported half-life of ~4 hours (MOTS-c-driven). The pharmacokinetic reference models an interval of weekly; this is not a measured community cadence or a dosing recommendation. Both mitochondrial peptides clear within hours, so neither builds up between weekly doses; the downstream metabolic effects are thought to outlast the plasma exposure. Pharmacokinetic source: Lee et al. Cell Metab 2015 and Hashimoto et al. PNAS 2001 component data. MOTS-C/Humanin Blend is a blend of Humanin and MOTS-c, so a reconstitution figure for it covers the combined vial contents rather than any single component. It is catalogued under Anti-Aging Peptides on WPA.
79 MOTS-C/Humanin Blend reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
WPA Analysis
The MOTS-C / Humanin blend pairs the two most-characterized members of the mitochondrial-derived peptide (MDP) family into a single pre-mixed reconstitution. The two molecules share an unusual molecular origin — both are short peptides encoded by small open reading frames within the mitochondrial ribosomal RNA genes, a finding that overturned the long-standing assumption that mitochondrial DNA encoded only the 13 known electron-transport-chain proteins. Humanin was the first of the family to be discovered, identified by Hashimoto et al. (PNAS 2001) from a cDNA-library screen of an Alzheimer's-disease brain searching for neuroprotective factors; it is a 24-amino-acid peptide encoded within the 16S rRNA region of the mitochondrial genome. MOTS-c followed roughly fifteen years later — Lee et al. (Cell Metabolism 2015), out of the Pinchas Cohen group at USC — as a 16-amino-acid peptide encoded within the 12S rRNA region, with downstream metabolic and exercise-mimetic activity. The Cohen group has gone on to characterize a broader MDP family (the SHLPs 1-6, additional 16S-encoded peptides) and has published the foundational human-plasma observational work tying circulating MDP levels to age, exercise status, and cardiometabolic risk.
The rationale for stacking the two MDPs into a single blend rests on the hypothesis that they target complementary downstream pathways from a shared mitochondrial-derived origin: MOTS-c is predominantly characterized for its metabolic and AMPK-activating effects in muscle and adipose tissue, while Humanin is predominantly characterized for its neuroprotective and IGFBP-3 / Bax-modulating activity in neuronal models. Neither molecule has produced an FDA-approved labeled indication anywhere in the world, neither has been formally trialed as a combination product, and there is no published controlled human study of the blend at any dose.
Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.
WPA DOSING INSIGHT
The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.
WPA RECONSTITUTION INSIGHT
Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.